Top 25 Companies in Global Alzheimers Disease Biomarkers Market (2024–2035): Expert View by Spherical Insights
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The global alzheimer’s disease biomarkers market describes the sector which creates and utilizes biological indicators that enable scientists to identify and monitor Alzheimer's disease development. Researchers use biomarkers which doctors can measure as biological indicators from blood samples and cerebrospinal fluid (CSF) and brain imaging to investigate disease progression in Alzheimer's patients and monitor their neurological changes. The medical field employs these biomarkers throughout clinical research and drug development and diagnostic testing to enhance initial patient identification and treatment strategies. Doctors use beta-amyloid proteins, tau proteins, phosphorylated tau, and neurofilament light chain as the main Alzheimer disease biomarkers which help them detect brain neurodegenerative patterns. Doctors now use advanced diagnostic technologies which combine positron emission tomography (PET) imaging with magnetic resonance imaging (MRI) and blood tests to identify Alzheimer's disease. The market is expanding rapidly because of two factors which include the growing elderly population and the increasing worldwide rates of neurodegenerative diseases. Healthcare organizations and research institutions are making substantial financial investments into biomarker discovery together with precision medicine systems to achieve better patient treatment results. Pharmaceutical companies now use biomarkers to establish specific Alzheimer's disease treatments which they study in clinical trials.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Alzheimer’s Disease Biomarkers Market.
Market Segmentation
Global Alzheimers Disease Biomarkers Market Size, By Type (CSF Biomarkers, Genetic Biomarkers, Blood Biomarkers), By Detection Technique (Molecular Diagnostics, Immunoassays), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035
Alzheimers disease biomarkers Market Size & Statistics
- The Market Size for Alzheimers Disease Biomarkers Was Estimated to be worth USD 960.79 Million in 2024.
- The Market is Going to Expand at a CAGR of 7.35% between 2024 and 2035.
- The Global Alzheimer’s Disease Biomarkers Market Size is anticipated to reach USD 2096.60 Million by 2035.
- North America is expected to generate the highest demand during the forecast period in the Alzheimer’s Disease Biomarkers Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Alzheimer’s Disease Biomarkers Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the alzheimers disease biomarkers market. Asia Pacific is expected to grow fastest due to increasing healthcare investments, rising prevalence of neurological disorders, and expanding diagnostic infrastructure in countries such as China, Japan, India, and South Korea. Growing awareness about early diagnosis of Alzheimer’s disease and increasing research initiatives in neurodegenerative diseases are also supporting market growth.
North America is expected to generate the highest demand during the forecast period in the alzheimers disease biomarkers market. North America is expected to generate the highest demand due to advanced healthcare infrastructure, strong research and development activities, and the presence of major pharmaceutical and biotechnology companies. Additionally, increasing government funding for Alzheimer’s research and the rising adoption of advanced diagnostic technologies are driving market expansion.
Ready to lead the Alzheimers disease biomarkers Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Alzheimers Disease Biomarkers Market
- Increasing Demand for Early Diagnosis of Alzheimer’s Disease
- Growing Development of Blood-Based Biomarker Tests
- Rising Investments in Neurodegenerative Disease Research
- Expansion of Biomarker-Based Drug Development
- Increasing Adoption of PET and MRI Imaging Technologies
- Growth in Personalized Medicine and Precision Diagnostics
- Technological Advancements in Biomarker Detection Methods
- Increasing Clinical Trials for Alzheimer’s Therapies
- Rising Aging Population Worldwide
- Expansion of AI and Data Analytics in Neurological Diagnostics
1. Increasing Demand for Early Diagnosis of Alzheimer’s Disease
Early diagnosis is critical for managing Alzheimer’s disease and improving treatment outcomes. Biomarker-based diagnostic tools help detect neurological changes before clinical symptoms become severe.
2. Growing Development of Blood-Based Biomarker Tests
Researchers are developing blood-based biomarker tests that allow non-invasive detection of Alzheimer’s disease. These tests provide a convenient and cost-effective alternative to traditional diagnostic methods.
3. Rising Investments in Neurodegenerative Disease Research
Governments, research institutions, and pharmaceutical companies are investing heavily in Alzheimer’s research. These investments are accelerating biomarker discovery and the development of advanced diagnostic tools.
4. Expansion of Biomarker-Based Drug Development
Biomarkers are increasingly used in clinical trials to evaluate the effectiveness of new Alzheimer’s treatments. They help researchers monitor disease progression and treatment responses more accurately.
5. Increasing Adoption of PET and MRI Imaging Technologies
Advanced imaging technologies such as PET and MRI scans are widely used to detect Alzheimer’s-related brain changes. These imaging biomarkers provide valuable insights into disease progression and neurological damage.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the alzheimer’s disease biomarkers market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 25 Companies Leading the Alzheimer’s Disease Biomarkers Market
- Roche Diagnostics
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
- Fujirebio Diagnostics Inc.
- Quanterix Corporation
- PerkinElmer Inc.
- Agilent Technologies Inc.
- GE HealthCare
- Danaher Corporation
- Beckman Coulter Inc.
- Eisai Co., Ltd.
- Biogen Inc.
- C2N Diagnostics LLC
- QIAGEN N.V.
- Myriad Genetics Inc.
- Becton Dickinson and Company
- Shimadzu Corporation
- Illumina Inc.
- Sysmex Corporation
- Alzheon Inc.
- Neurotrack Technologies
- ADx NeuroSciences
- Quest Diagnostics Incorporated
1. Roche Diagnostics
Headquarters: Basel, Switzerland
Roche Diagnostics operates as a worldwide leader in the development of in vitro diagnostic tests and biotechnology products. The company creates cutting-edge diagnostic tests which use biomarker technology to diagnose neurological disorders including Alzheimer's disease. Roche develops laboratory testing systems which provide highly accurate results and systems for detecting biomarkers. Its diagnostic solutions enable the identification of diseases at early stages while supporting clinical research activities and customized medical treatments. The company conducts its business operations throughout the world while maintaining strong research and development facilities. Through its ongoing development of new products and its collaborations with medical institutions Roche Diagnostics establishes itself as a key player in the Alzheimer’s disease biomarker testing market.
2. Thermo Fisher Scientific Inc.
Headquarters: Waltham, Massachusetts, USA
Thermo Fisher Scientific Inc. stands as the top company which supplies scientific research equipment and diagnostic equipment and laboratory products. The company creates innovative biomarker testing instruments which researchers use to study neurological disorders and conduct clinical diagnostic tests. Thermo Fisher uses sophisticated analytical equipment and research platforms to enhance its biomarker discovery capabilities. The company provides solutions which customers use in pharmaceutical research and clinical trials and medical diagnostic procedures. The company operates worldwide while making substantial investments to advance life sciences research and innovative technologies. Thermo Fisher Scientific through its complete product range makes a major impact on the Alzheimer’s disease biomarkers market.
3. Siemens Healthineers AG
Headquarters: Erlangen, Germany
Siemens Healthineers AG operates as a worldwide medical technology firm which specializes in diagnostic imaging and laboratory diagnostic services. The company creates advanced imaging systems which include PET and MRI technologies that medical professionals use to detect Alzheimer’s disease. Siemens Healthineers focuses on integrating digital technologies and artificial intelligence into diagnostic solutions. Its imaging and diagnostic systems help detect neurological abnormalities which people with Alzheimer’s disease exhibit. The company conducts its business worldwide while it operates advanced research and development facilities. Through continuous technological innovation Siemens Healthineers maintains its position as a major player in the Alzheimer’s disease biomarkers market.
4. Bio-Rad Laboratories Inc
Headquarters: Hercules, California, USA
Bio-Rad Laboratories Inc. functions as a biotechnology firm which delivers research products and clinical diagnostic solutions. The company creates technologies for biomarker detection which researchers use to investigate neurological disorders and perform medical diagnoses. Bio-Rad provides advanced laboratory instruments and reagents which researchers use to discover biomarkers and conduct clinical tests. Research institutions and pharmaceutical companies widely use the company's technologies. The company maintains operations in multiple countries while establishing a strong foothold in scientific research markets. Bio-Rad drives progress in the Alzheimer’s disease biomarkers market by developing new products and making continuous innovations.
5. Abbott Laboratories
Headquarters: Abbott Park, Illinois, USA
Abbott Laboratories operates as an international healthcare company that focuses on developing diagnostic solutions and medical devices and pharmaceutical products and nutritional products. The company develops diagnostic technologies used in neurological disease detection and biomarker analysis. Abbott develops advanced laboratory testing platforms which help hospitals and clinics to detect and monitor diseases more effectively. The company provides diagnostic solutions which hospitals and laboratories and research institutions use throughout the world. The company invests heavily in research and development to advance healthcare technologies. Abbott Laboratories uses its worldwide presence and innovative skills to establish itself as a key player in the Alzheimer's disease biomarkers market.
Are you ready to discover more about the alzheimer’s disease biomarkers market?
The report provides an in-depth analysis of the leading companies operating in the global alzheimer’s disease biomarkers market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Roche Diagnostics
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
- Fujirebio Diagnostics Inc.
- Quanterix Corporation
- PerkinElmer Inc.
- Agilent Technologies Inc.
- Others.
Conclusion
The global market for alzheimer’s disease biomarkers shows substantial growth because neurodegenerative diseases occur more frequently and people need early diagnostic tests and research funding for neurological studies continues to increase. Biomarkers play a critical role in improving disease detection, monitoring disease progression, and supporting drug development. The market expansion receives support through technological advancements that improve diagnostic imaging systems and biomarker detection technologies and blood-based testing methods. The main companies in the field which include roche diagnostics and thermo fisher scientific and siemens healthineers and bio-rad laboratories and abbott laboratories make significant investments into research and development to enhance their diagnostic systems. alzheimer's disease biomarkers have become essential for contemporary healthcare systems because they enable doctors to identify neurodegenerative diseases at an earlier stage while providing better treatment options.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?